Skip to main content

Storage & Overactive Bladder Pharmacotherapy

Pharmacologic therapy for overactive bladder (OAB) and neurogenic lower urinary tract dysfunction (NLUTD) works through two complementary mechanisms at the detrusor: blocking cholinergic contraction (antimuscarinics) or stimulating sympathetic relaxation (β3-agonists). A third distinct agent — desmopressin — addresses nocturnal polyuria rather than storage per se.

This subcategory covers the three drug classes relevant to storage-phase pharmacotherapy. For the full clinical framework see the AUA/SUFU OAB guideline and the OAB clinical-condition article.

  • Anticholinergic / Antimuscarinic AgentsSix FDA-approved agents — oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, trospium. Mechanism, efficacy (Cochrane 2023 data), head-to-head comparisons, dry mouth burden, the dementia controversy (SUFU 2022 white paper), and contemporary AUA positioning.
  • β3-Adrenergic Receptor AgonistsMirabegron and vibegron — mechanism (β3 → cAMP → detrusor relaxation), FDA indications including the 2024 vibegron BPH-OAB expansion (COURAGE trial), efficacy comparable to antimuscarinics with superior tolerability, combination therapy with solifenacin, and cognitive-risk counseling without anticholinergic burden.
  • DesmopressinSynthetic vasopressin analogue for nocturnal polyuria and nocturia. Oral and nasal routes, formulation-specific dosing (including sex-specific sublingual dosing), hyponatremia monitoring, labeled indications, and the NOCDURNA FDA approval.
  • Botulinum Toxin (OnabotulinumtoxinA)Botox® for refractory non-neurogenic OAB (FDA 2013, 100 U) and neurogenic detrusor overactivity (FDA 2011, 200 U). SNARE-cleavage mechanism with dual motor and sensory effects; pivotal Nitti / Chapple / Cruz / Ginsberg trials; CISC and UTI risk; formulation comparison across Dysport, Xeomin, MyoBloc, Daxxify.

Contemporary Treatment Selection (AUA/SUFU 2024)​

Offer bladder training and behavioral measures, and choose additional treatment through shared decision-making. Options include antimuscarinic or β3-agonist medication, combination pharmacotherapy after inadequate monotherapy response, and minimally invasive treatment such as intradetrusor onabotulinumtoxinA, sacral neuromodulation or tibial nerve stimulation. The guideline permits minimally invasive therapy without requiring prior behavioral or medication trials. Discuss antimuscarinic cognitive risk, medication tolerability, catheterization/UTI risk and treatment burden when choosing among options. See the AUA/SUFU guideline.